Scarica l'app Stockscreener
2.93
1.91%
0.05
Precedente Chiudi:
$2.88
Aprire:
$2.87
Volume 24 ore:
6,419
Relative Volume:
0.03
Capitalizzazione di mercato:
$101.53M
Reddito:
-
Utile/perdita netta:
$-27.66M
Rapporto P/E:
-3.0842
EPS:
-0.95
Flusso di cassa netto:
$-24.36M
1 W Prestazione:
+8.70%
1M Prestazione:
-4.71%
6M Prestazione:
-0.84%
1 anno Prestazione:
-13.68%
Intervallo 1D:
$2.86
$3.0099
Intervallo di 1 settimana:
$2.72
$3.1541
Portata 52W:
$1.60
$5.885
Genelux Corp Stock (GNLX) Company Profile
Nome
Genelux Corp
Settore
Industria
Telefono
805-267-9889
Indirizzo
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Confronta GNLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.935 | 101.53M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.04 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
611.55 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.39 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.84 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.47 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-29 | Iniziato | Guggenheim | Buy |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-11-27 | Iniziato | H.C. Wainwright | Buy |
| 2023-09-12 | Iniziato | Maxim Group | Buy |
| 2023-02-15 | Iniziato | The Benchmark Company | Speculative Buy |
Genelux Corp Borsa (GNLX) Ultime notizie
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Raymond James Financial Inc. Takes $41,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Benchmark maintains $25 target on Genelux stock, optimistic on trials - Investing.com
Benchmark maintains $25 target on Genelux stock, optimistic on trials By Investing.com - Investing.com India
What is HC Wainwright’s Forecast for Genelux Q1 Earnings? - Defense World
Analysts Offer Predictions for Genelux Q1 Earnings - Defense World
Genelux (NASDAQ:GNLX) Given Buy Rating at HC Wainwright - Defense World
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements - TipRanks
H.C. Wainwright maintains Buy on Genelux shares, target at $30 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Genelux shares, target at $30 - Investing.com
Genelux Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Brokers Set Expectations for Genelux FY2024 Earnings - Defense World
Research Analysts Set Expectations for Genelux Q1 Earnings - The AM Reporter
Genelux reports FY24 EPS (95c), consensus (88c) - TipRanks
FDA Green Light: Genelux's Cancer Drug Olvi-Vec Advances as 2024 Data Shows 71% Disease Control - Stock Titan
GENELUX Corp SEC 10-K Report - TradingView
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround - Yahoo Finance
Genelux (GNLX) Projected to Post Quarterly Earnings on Friday - Defense World
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp. - TipRanks
What is HC Wainwright’s Estimate for Genelux Q1 Earnings? - Defense World
Benchmark maintains $25 target on Genelux following trial data - Investing.com
Genelux’s (GNLX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Genelux stock holds Buy rating, $30 target from H.C. Wainwright - Investing.com India
Genelux prices 3M shares at $3.50 in underwritten public offering - TipRanks
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec - TipRanks
Genelux announces alignment with FDA of approval pathway for Olvi-Vec - TipRanks
Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial - MarketScreener
Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell - Nasdaq
Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study - Marketscreener.com
Genelux Prices $10.5 Million Stock Offering - MarketScreener
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock - GlobeNewswire
$10.5M Capital Raise: How Genelux Plans to Accelerate Cancer Drug Pipeline - Stock Titan
Breakthrough: Cancer Drug Achieves 79% Tumor Reduction in Advanced Lung Cancer Study - Stock Titan
Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D.A. Davidson & CO. Makes New $51,000 Investment in Genelux Co. (NASDAQ:GNLX) - Defense World
Apollon Wealth Management LLC Grows Stock Holdings in Genelux Co. (NASDAQ:GNLX) - Defense World
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth? - simplywall.st
Genelux Corporation (NASDAQ:GNLX) Announces CFO Transition and Appointment of New CFOGenelux Corporation, a leading biotechnology company, recently disclosed in an SEC filing that Lourie Zak has resigned as Chief Financial Officer, effective imm - Defense World
Genelux Corporation Announces Matt Pulisic Serves as Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Genelux appoints new CFO as Lourie Zak departs - MSN
Genelux Corporation Announces New Chief Financial Officer - Markets Insider
GNLXGenelux Corp Latest Stock News & Market Updates - Stock Titan
Genelux appoints new CFO amid clinical advancements - Investing.com
Genelux Corp. Appoints New CFO Amid Leadership Change - TipRanks
Ex-Arrowhead & Amgen Executive Takes CFO Role at Genelux: Key Details on Strategic Appointment - Stock Titan
Oncolytic Viruses Market Expected to rise, 2034 | Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen - Barchart
Genelux (GNLX) Stock Price, News & Analysis - MarketBeat
We Think Genelux (NASDAQ:GNLX) Needs To Drive Business Growth Carefully - Yahoo Finance
Could Genelux's Olvi-Vec Emerge As A Powerful Tool In The Fight Against Difficult-to-treat Cancers? - RTTNews
Geode Capital Management LLC Has $749,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Corp Azioni (GNLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):